Domov › Miastenija gravis › Texas
Klinične študije za Miastenija gravis v Texas
18 študij za Miastenija gravis išče udeležence na lokacijah v Texas.
Mesta v Texas
Uradno besedilo študije (angleško)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Austin Neuromuscular Center, Austin
- Texas Neurology, Dallas
Vključevanje udeležencevFaza 3
Starost 18–74 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Cinical Study Site, Houston
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07647510ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- National Neuromuscular Research Institute, Austin
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- National Neuromuscular Research Institute, Austin
- University of Texas- San Antonio - Health Science Center - PPDS, San Antonio
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- National Neuromuscular Research Institute, Austin
- University of Texas- San Antonio - Health Science Center - PPDS, San Antonio
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07284420Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Baylor Scott & White Research Institute - Baylor Scott & White Research Institute, Dallas
- ANESC Research, El Paso
- Baylor Scott & White Neurology - McKinney, McKinney
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Nerve and Muscle Center of Texas - Neurology, Houston
- Texas Institute for Neurological Disorders, Sherman
- Neurology Care Clinic, Waxahachie
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07501702A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
- Austin Neuromuscular Center, Austin
Vključevanje udeležencevFaza 2
Starost 2–17 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT06987539RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
Vključevanje udeležencevFaza 1/2
Starost 18–70 · Vsi spoli · Posodobljeno 13. avg. 2026 · NCT06359041Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Houston
Vključevanje udeležencevFaza 1/2
Starost 18–85 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT07596901Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1003, Dallas
- Site Number - 1047, Denton
- Site Number - 1057, Houston
- in še 1
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 30. jul. 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Houston Methodist Hospital, Houston
Vključevanje udeležencevFaza 2/3
Starost 18–75 · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT06193889A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Neurological Institute, Houston
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. jun. 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UT Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 25. feb. 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Dallas
- Clinical Trial Site, Houston
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 18. feb. 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- National Neuromuscular Research Institute, Austin
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 17. feb. 2026 · NCT06298565A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
- Nerve & Muscle Center of Texas, Houston
- Houston Methodist Neurological Institute, Houston
Vključevanje udeležencevFaza 1/2
Starost 18–74 · Vsi spoli · Posodobljeno 11. feb. 2026 · NCT07250750Vitaccess Real MG Registry
- University of Texas Health Science Center at Houston, Houston
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 29. jul. 2025 · NCT06064461Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.